RhumbLine Advisers
XFOR icon

RhumbLine Advisers’s X4 Pharmaceuticals XFOR Stock Holding History

RhumbLine Advisers’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,281
Closed -$44.5K – 4273
2025
Q1 		$44.5K Buy
6,281
+323
+5% +$4.45K ﹤0.01% 3603
2024
Q4 		$131K Buy
5,958
+9
+0.2% +$143 ﹤0.01% 3391
2024
Q3 		$119K Sell
5,949
-293
-5% -$6.11K ﹤0.01% 3451
2024
Q2 		$109K Buy
6,242
+795
+15% +$26K ﹤0.01% 3499
2024
Q1 		$227K Buy
5,447
+101
+2% +$2.81K ﹤0.01% 3108
2023
Q4 		$135K Hold
5,346
– – ﹤0.01% 3352
2023
Q3 		$175K Buy
5,346
+215
+4% +$9.38K ﹤0.01% 3231
2023
Q2 		$299K Buy
+5,131
New +$264K ﹤0.01% 3021
2021
Q2 		– Sell
-688
Closed -$178K – 3118
2021
Q1 		$178K Sell
688
-25
-4% -$6.57K ﹤0.01% 2859
2020
Q4 		$138K Buy
713
+113
+19% +$22.2K ﹤0.01% 2918
2020
Q3 		$122K Sell
600
-52
-8% -$12.5K ﹤0.01% 2833
2020
Q2 		$182K Buy
+652
New +$179K ﹤0.01% 2806

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RhumbLine Advisers's XFOR Position: Q2 2025 in Review

RhumbLine Advisers sold out of X4 Pharmaceuticals (XFOR) in Q2 2025, closing a stake of 6,281 shares — an estimated $44.5K sold.

RhumbLine Advisers first reported a position in XFOR in Q2 2020 and held it in 12 quarters. The position peaked at $299K in Q2 2023. 51 funds tracked by Wall St. Rank hold XFOR as of Q2 2025.

  • RhumbLine Advisers reported no remaining X4 Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 6,281 X4 Pharmaceuticals shares in Q2 2025, an estimated $44.5K.
  • RhumbLine Advisers first reported a position in X4 Pharmaceuticals in Q2 2020 and held it in 12 quarters.
  • RhumbLine Advisers's X4 Pharmaceuticals position peaked at $299K in Q2 2023.
  • 51 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.